SINOVAC Board of Directors Prevails Against Advantech/Prime’s Lawsuit in Hong Kong
The Board of Directors of SINOVAC Biotech Ltd. (
NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has prevailed against the latest lawsuit filed by Advantech/Prime Success (“Advantech/Prime”) in Hong Kong. This result follows Advantech/Prime’s recently failed petition in New York last week, which was a repeated attempt by the purported PIPE Investors to block or delay a hearing for interim relief sought by the Company et al at the Antiguan High Court and to interfere with the payment of the US$55.00 per common share special cash dividend to valid shareholders of the Company as declared by the current SINOVAC Board.
SINOVAC Board of Directors Files Investor Presentation Outlining Decisive Actions to Protect Shareholder Interests
The Board of Directors of SINOVAC Biotech Ltd. (
NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has filed an investor presentation with the U.S. Securities and Exchange Commission (SEC) as a Form 6-K and launched a website, www.VoteSinovac.com, with important information and resources in connection with the upcoming Special Meeting of Shareholders (the “Special Meeting”) to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time).
SINOVAC Board of Directors Prevails Against Advantech/Prime’s New York Lawsuit
SINOVAC Biotech Ltd. (
NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has prevailed against Advantech/Prime Success’ (“Advantech/Prime”) Petition for Emergency Injunctive Relief in the U.S. District Court for the Southern District of New York.
SINOVAC Board of Directors Files Definitive Proxy Materials
The Board of Directors of SINOVAC Biotech Ltd. (
NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has filed its definitive proxy materials with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time).
SINOVAC Board of Directors Provides Update on Special Dividend Payment and Commitment to Delivering Value to All Shareholders
The Board of Directors of SINOVAC Biotech Ltd. (
NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced several important decisions to deliver sustainable value to shareholders and strengthen the Company’s governance framework.
